Indonesia, Central Java (2015)
Sample size
|
3000 |
Response rate
|
99.4% |
RAAB version
|
RAAB6 |
Diabetic retinopathy
|
No |
Disability module
|
No |
Vision impairment
Prevalence (age-sex adjusted)
Female
|
Male
|
Total
|
|||||||
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Blind
|
110 200
|
3.2
|
2.4 - 4.0
|
66 778
|
2.1
|
1.0 - 3.2
|
176 978
|
2.7
|
1.9 - 3.4
|
Severe
|
105 469
|
3.1
|
2.2 - 3.9
|
80 810
|
2.5
|
1.7 - 3.4
|
186 279
|
2.8
|
2.2 - 3.4
|
Moderate
|
367 016
|
10.6
|
9.0 - 12.3
|
260 041
|
8.1
|
5.7 - 10.5
|
627 058
|
9.4
|
7.7 - 11.1
|
Mild
|
469 899
|
13.6
|
11.6 - 15.6
|
335 814
|
10.5
|
8.0 - 13.0
|
805 713
|
12.1
|
10.2 - 14.1
|
Cataract
Operable cataract prevalence (age-sex adjusted)
Female
|
Male
|
Total
|
|||||||
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
<3/60
|
55 525
|
1.6
|
1.0 - 2.2
|
22 700
|
0.7
|
0.0 - 1.7
|
78 224
|
1.2
|
0.6 - 1.8
|
<6/60
|
119 064
|
3.4
|
2.4 - 4.5
|
59 716
|
1.9
|
0.8 - 3.0
|
178 780
|
2.7
|
1.8 - 3.5
|
<6/18
|
325 560
|
9.4
|
7.6 - 11.2
|
195 228
|
6.1
|
4.1 - 8.2
|
520 788
|
7.8
|
6.3 - 9.4
|
<6/12
|
617 850
|
17.9
|
15.3 - 20.5
|
413 405
|
12.9
|
9.4 - 16.5
|
1 031 255
|
15.5
|
12.9 - 18.1
|
Cataract surgical coverage (CSC) (age-sex adjusted)
Female
|
Male
|
Total
|
|||||||
|
|
%
|
95% CI
|
|
%
|
95% CI
|
|
%
|
95% CI
|
CSC<3/60
|
-
|
32.8
|
14.9 - 50.7
|
-
|
44.4
|
10.8 - 10.8
|
-
|
36.6
|
16.7 - 48.9
|
CSC<6/60
|
-
|
18.5
|
6.4 - 30.6
|
-
|
23.3
|
8.7 - 37.9
|
-
|
20.2
|
8.8 - 28.3
|
CSC<6/18
|
-
|
10.4
|
4.5 - 16.3
|
-
|
9.4
|
4.0 - 14.8
|
-
|
10.0
|
6.0 - 14.8
|
CSC<6/12
|
-
|
6.0
|
2.7 - 9.4
|
-
|
5.9
|
2.6 - 9.1
|
-
|
6.0
|
3.6 - 8.4
|
Effective cataract surgical coverage (eCSC) (age-sex adjusted)
The RAAB research team are in the process of concluding a formal analysis of eCSC with the World Health Organization and the Vision Loss Expert Group. eCSC results will be available on the repository in 2022.
Refractive error
Vision impairing refractive error is defined as presenting VA less than 6/12 improving to 6/12 with pinhole. Use of presenting VA accounts for the prevalence of uncorrected or undercorrected refractive error only.
Vision impairing refractive error prevalence (age-sex adjusted)
Female
|
Male
|
Total
|
|||||||
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Extrapolated magnitude
|
%
|
95% CI
|
Blind
|
2 714
|
0.1
|
0.0 - 0.2
|
0
|
0.0
|
0.0 - 0.0
|
2 714
|
0.0
|
0.0 - 0.1
|
Severe
|
0
|
0.0
|
0.0 - 0.0
|
3 077
|
0.1
|
0.0 - 0.3
|
3 077
|
0.0
|
0.0 - 0.1
|
Moderate
|
21 957
|
0.6
|
0.3 - 1.0
|
27 561
|
0.9
|
0.3 - 1.4
|
49 517
|
0.7
|
0.5 - 1.0
|
Mild
|
268 637
|
7.8
|
6.3 - 9.3
|
185 505
|
5.8
|
4.1 - 7.5
|
454 143
|
6.8
|
5.5 - 8.2
|
Effective refractive error coverage (eREC) (age-sex adjusted)
The RAAB research team are in the process of concluding a formal analysis of eREC with the World Health Organization and the Vision Loss Expert Group. eREC results will be available on the repository in 2022.
Notes
Vision impairment categories defined according to WHO thresholds using presenting visual acuity in the better eye.
All prevalence and coverage estimates are adjusted to the age and gender distribution of the population 50 years and older in the survey area.
All 95% confidence intervals adjusted to account for the cluster design of the survey.